Esperion Therapeutics (NASDAQ:ESPR) has been under a strong bear grip, hence the stock is down -34.22% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 6.75% in the past 1 week. The stock has risen by 8.12% in the past week indicating that the buyers are active at lower levels, but the stock is down -33.15% in the past 4 weeks.
The company shares have dropped -87.50% from its 1 Year high price. On Jul 20, 2015, the shares registered one year high at $100.98 and the one year low was seen on Jun 29, 2016. The 50-Day Moving Average price is $15.31 and the 200 Day Moving Average price is recorded at $16.45.
The stock has recorded a 20-day Moving Average of 23.2% and the 50-Day Moving Average is 27.24%.
Esperion Therapeutics (NASDAQ:ESPR): stock turned positive on Friday. Though the stock opened at $10.58, the bulls momentum made the stock top out at $11.3697 level for the day. The stock recorded a low of $10.52 and closed the trading day at $11.19, in the green by 6.17%. The total traded volume for the day was 704,397. The stock had closed at $10.54 in the previous days trading.
In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Esperion Therapeutics, Inc., Mcgovern Mark E, had purchased 5,000 shares in a transaction dated on July 5, 2016. The transaction was executed at $10 per share with total amount equaling $50,000.
Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of patients with hypercholesterolemia and other cardio-metabolic risk markers. The Companys primary activities include conducting research and development activities, including nonclinical, preclinical and clinical testing, performing business and financial planning, recruiting personnel, and raising capital. ETC-1002, the Companys lead product candidate, is an orally available, once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with other LDL-cholesterol lowering therapies currently available. ETC-1002 is being developed for patients with hypercholesterolemia. One completed Phase IIb clinical study and a second that is nearing completion build upon a Phase I and Phase II clinical development program for ETC-1002.